Edition:
India

Michael Erman

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

18 Oct 2017

New cancer drugs help J&J top profit estimates

Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.

17 Oct 2017

U.S. judge in Texas invalidates Allergan patents on Restasis

A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

14 Oct 2017

U.S. hospital, insurer stocks drop after Trump ends subsidies

NEW YORK Shares of U.S. hospital companies and health insurers fell on Friday after President Donald Trump said he would cut off Obamacare subsidies to health insurance companies for low-income patients, a move that could make healthcare less affordable next year for some people.

13 Oct 2017

Allergan settles with one of four companies contesting Restasis patent

Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

06 Oct 2017

Senator McCaskill drafts bill in response to Allergan patent maneuver

NEW YORK Democratic U.S. Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U.S. Patent and Trademark Office review of a patent.

05 Oct 2017

Senator McCaskill drafts bill in response to Allergan patent maneuver

NEW YORK, Oct 5 Democratic U.S. Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U.S. Patent and Trademark Office review of a patent.

05 Oct 2017

Mylan surges, Teva slumps after FDA approves Copaxone copy

Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.

04 Oct 2017

Allergan CEO says patent review flawed in response to senators

NEW YORK Allergan Plc Chief Executive Brent Saunders on Tuesday defended his company's decision to transfer drug patents to a Native American tribe as a proper way to shield them from a flawed patent review process, in a response to congressional criticism.

04 Oct 2017

U.S. House committee launches probe of Allergan patent deal

NEW YORK A U.S. House of Representatives committee launched a probe into drugmaker Allergan Plc's deal to transfer some of its patents to a Native American tribe to shield them from review.

03 Oct 2017

Allergan CEO says patent review flawed in response to senators

NEW YORK, Oct 3 Allergan Plc Chief Executive Brent Saunders on Tuesday defended his company's decision to transfer drug patents to a Native American tribe as a proper way to shield them from a flawed patent review process, in a response to congressional criticism.

Markets

  • Asia
  • U.S.
  • Europe
  • Sectors
Stock Search
Sensex 32,389.96 -194.39 -0.60%
Nikkei 21,457.64 + 9.12 +0.04%
Hang Seng 28,487.24 + 328.15 +1.17%
EUR/INR 76.724 -0.38%
USD/INR 65.015 +0.04%
GBP/INR 85.592 +0.10%
Gold 1,279.60 -7.30 -0.57%
Oil 50.91 -0.38 -0.74%
Corn 348.25 -0.75 -0.21%